Media coverage about Hutchison China MediTech (NASDAQ:HCM) has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hutchison China MediTech earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.1387269280109 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several brokerages have issued reports on HCM. BidaskClub lowered Hutchison China MediTech from a “buy” rating to a “hold” rating in a report on Tuesday, March 20th. Zacks Investment Research lowered Hutchison China MediTech from a “hold” rating to a “sell” rating in a report on Thursday, March 15th.
Shares of NASDAQ:HCM opened at $29.67 on Friday. The company has a market capitalization of $4,006.75, a price-to-earnings ratio of -134.86 and a beta of 0.40. Hutchison China MediTech has a 52-week low of $18.00 and a 52-week high of $42.25.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Hutchison China MediTech (HCM) Stock Price” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-hutchison-china-meditech-hcm-stock-price.html.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.